Navigation Links
Favrille Announces Resolution of Debt Obligations and Plans for Maximizing Assets
Date:7/7/2008

cility and other assets over the past few weeks," said John P. Longenecker, Ph.D., President and Chief Executive Officer of Favrille. "The future direction of the Company going forward remains uncertain but could include either a reorganization which might involve in-licensing of products contingent upon additional financing, a merger with another entity or liquidation of the Company either inside or outside of bankruptcy. We will continue to explore the relative benefits of all these options. The management and board of directors of Favrille remain committed to addressing these issues and maximizing the value of our assets as expeditiously as possible."

About Favrille, Inc.

Favrille, Inc. is a biopharmaceutical company focused on the development and commercialization of targeted immunotherapies for the treatment of cancer and other diseases of the immune system.

Statements in this press release that are not strictly historical in nature constitute "forward-looking statements." Such statements include, but are not limited to, references to Favrille's product candidates, proprietary technologies and research and clinical development programs. Such forward- looking statements involve known and unknown risks, uncertainties and other factors that may cause Favrille's actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. These factors include, but are not limited to, risks and uncertainties related to Favrille's ability to continue its operations, conserve cash or recognize value on our assets and additional risks discussed in Favrille's filings with the Securities and Exchange Commission. All forward-looking statements are qualified in their entirety by this cautionary statement. Favrille is providing this information as of the date of this release and, except as required by law, does not undertake any obligation to update any forward-looking statements containe
'/>"/>

SOURCE Favrille, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Favrille CEO to Present at NewsMakers in the Biotech Industry Investment Conference
2. Favrille CEO to Present at Bear Stearns Healthcare Conference
3. Favrille to Present at AG Edwards Emerging Growth Conference and Wall Street Analyst Forum
4. Favrille to Present at BIO InvestorForum
5. Favrille to Host Conference Call and Live Webcast to Discuss Third Quarter 2007 Financial Results on October 25, 2007
6. Favrille to Present at BIOCOM Investor Conference, Acumen BioFin Rodman & Renshaw Healthcare Conference and CIBC World Markets Healthcare Conference
7. Favrille Announces $21.1 Million Registered Direct Offering
8. Favrille Reports Fourth Quarter and Year End 2007 Financial Results
9. Favrille to Host Conference Call and Live Webcast to Discuss First Quarter 2008 Financial Results on May 8, 2008
10. Favrille Reports First Quarter 2008 Financial Results
11. Favrille Announces Results from Phase 3 Registration Trial of Specifid in Patients with Follicular B-Cell Non-Hodgkins Lymphoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... ... August 27, 2015 , ... Capital Edge Consulting , a nationwide ... pleased to announce their ranking as one of the top 5000 companies listed on ... companies across the nation. , “It is truly an honor to be recognized as ...
(Date:8/27/2015)... BIOREM Inc. (TSXV: BRM) ("Biorem" or "the Company") today announced its ... Biorem,s complete second quarter financial statements and MD&A have been filed ... earnings per shareThree-months ended , Six -months endedJune 30 , June ... , 2014 Revenue , 4,709 , 2,459 ... 1,656 , 56 , 3,188 ...
(Date:8/27/2015)... TRIANGLE PARK, N.C. , Aug. 27, 2015 ... on the decision by FedEx, UPS and The ... of certain biological specimens classified as ,select agents, ... and long history of handling these sensitive shipments. ... knowledge of global transportation regulations, trained and certified ...
(Date:8/26/2015)... Heights, MO (PRWEB) , ... August 26, 2015 ... ... announcing it is increasing its investment in the development and manufacture of highly ... demand. The company’s scientific team's extensive expertise with protein chemistry has led ...
Breaking Biology Technology:Capital Edge Consulting Makes Inc. 5000 List of America’s Fastest-Growing Private Companies 2Capital Edge Consulting Makes Inc. 5000 List of America’s Fastest-Growing Private Companies 3BIOREM Reports $718,000 Net Earnings for the Second Quarter 2BIOREM Reports $718,000 Net Earnings for the Second Quarter 3Marken Ensures Safe Transportation Of Select Agents And Toxins 2Lee Biosolutions Announces Increased Investment in the Development and Manufacturing of Biomarkers Used in Early Detection Of Heart Disease 2
... ... , ... (Vocus) November 12, 2009 -- DuPont and Dow AgroSciences, a wholly owned subsidiary ... agreement that will enable the two companies to deliver expanded herbicide-tolerant soybean options to farmers ...
... Biotechnology, Inc. (OTC Bulletin Board: CSBR), an oncology ... accelerating the development and enhancing the value of oncology drugs, ... in oncology drug development and personalized medicine have been selected ... conference in Boston. , A poster will be ...
... ... Consulting to provide government business development services to its technology incubator companies, bringing a potential ... ... Consulting has signed a Memorandum of Understanding with the University of Florida ...
Cached Biology Technology:DuPont, Dow AgroSciences Agree to Cross License Next-Generation Soybean Herbicide Tolerant Traits 2DuPont, Dow AgroSciences Agree to Cross License Next-Generation Soybean Herbicide Tolerant Traits 3DuPont, Dow AgroSciences Agree to Cross License Next-Generation Soybean Herbicide Tolerant Traits 4Champions Biotechnology to Present Data at AACR-EORTC 2009 Regarding the Predictability of Biomerk Tumorgraft(TM) Platform to Guide Personalized Cancer Treatment and Accelerate Oncology Drug Development 2Champions Biotechnology to Present Data at AACR-EORTC 2009 Regarding the Predictability of Biomerk Tumorgraft(TM) Platform to Guide Personalized Cancer Treatment and Accelerate Oncology Drug Development 3Champions Biotechnology to Present Data at AACR-EORTC 2009 Regarding the Predictability of Biomerk Tumorgraft(TM) Platform to Guide Personalized Cancer Treatment and Accelerate Oncology Drug Development 4New Program to Bring University of Florida Incubator Companies Millions in New Contracts 2New Program to Bring University of Florida Incubator Companies Millions in New Contracts 3New Program to Bring University of Florida Incubator Companies Millions in New Contracts 4
(Date:8/20/2015)... , Aug. 20, 2015 The wearable ... that are active and healthy. However, wearable technology ... hospital environment to help improve diagnostic capabilities and ... from the Wearable Technologies Conference 2015 , ... applications for wearables in healthcare.    ...
(Date:8/20/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ... growing mobile commerce market and creator of the Wocket® ... Alliance and the EMV Migration Forum.  ... Alliance Latin America (SCALA) Chapter provides NXT-ID, Inc. direct ... promoting adoption of smart card technology. To ...
(Date:8/18/2015)... , Aug. 18, 2015  Navitas today ... contributor to the Submission Content Management webinar ... a non-profit forum. Dedicated to the Implementation of ... neutral platform for industry, vendors, health authorities, ... and work towards a standard method of ...
Breaking Biology News(10 mins):Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 2Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 3NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 2NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 3NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 4Navitas, a Key Contributor in IRISS Forum Webinar 2Navitas, a Key Contributor in IRISS Forum Webinar 3
... throughout the world and ensuring safe water supplies would do ... any other possible measure, according to an analysis released today ... water and sanitation reduces poverty in three ways. ... entrepreneurs; , Significant savings are achieved in the ...
... Researchers have discovered a mechanism for the rapid growth seen ... The tumors, which are made up of proliferating blood ... descent, with girls more frequently afflicted than boys. The ... blood-red lump on the head or facethen grow rapidly in ...
... Missouri Botanical Garden in St. Louis operates one of ... and the second largest in the western hemisphere. With ... a gigantic new aroid species from Ecuador, the ... has reached a milestone of six million specimens. ...
Cached Biology News:Providing toilets, safe water is top route to reducing world poverty: UN University 2Providing toilets, safe water is top route to reducing world poverty: UN University 3Providing toilets, safe water is top route to reducing world poverty: UN University 4Providing toilets, safe water is top route to reducing world poverty: UN University 5Researchers identify Achilles heel of common childhood tumor 2Missouri Botanical Garden mounts milestone 6 millionth herbarium specimen 2Missouri Botanical Garden mounts milestone 6 millionth herbarium specimen 3
PC12 (rat phaeochromocytoma) cells Source: Cell Lysate Form: Ready to Use Application: Western Blotting Control...
Molecular Biological Resources offers bulk quantities of existing protein products. Please see the Chimerx divisions website for existing products and contact lloconne@molbiores.com for pricing....
...
...
Biology Products: